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Background:  In October  2012,  the  Meningococcal  A  conjugate  vaccine  MenAfriVac  was  granted  a  label
variation  to allow  for its  use in  a controlled  temperature  chain  (CTC),  at temperatures  of  up  to 40 ◦C for
not  more  than  four  days.  This  paper  describes  the  ﬁrst ﬁeld  use  of MenAfriVac  in a CTC  during  a  campaign
in  Benin,  December  2012,  and  assesses  the  feasibility  and  acceptability  of  the  practice.
Methods: We  implemented  CTC  in  one  selected  district,  Banikoara  (target  population  of 147,207;  1–29
years  of  age),  across  14 health  facilities  and  150 villages.  We  monitored  the  CTC  practice  using  temper-
ature  indicators  and  daily  monitoring  sheets.  At the  end  of  the  campaign  we conducted  a  face-to-face
survey  to assess  vaccinators’  and  supervisors’  experience  with  CTC.
Findings: A  mix  of  strategies  were  implemented  in  the  ﬁeld  to  maximize  the  beneﬁts  from  CTC  practice,
depending  on the  distance  from  health  centre  to  populations  and  the  availability  of a  functioning  refrig-
erator  in  the  health  centre.  Coverage  across  Banikoara  was  105.7%.  Over  the  course  of  the  campaign  only
nine  out  of  approx.  15,000  vials  were  discarded  due  to  surpassing  the 4  day  CTC limit and  no  vial was
discarded  because  of  exposure  to  a temperature  higher  than  40 ◦C or due  to  the  Vaccine  Vial  Monitorut of the cold chain
ogistics
(VVM)  reaching  its  endpoint.  Overall  conﬁdence  and  perceived  usefulness  of the  CTC  approach  were  very
high  among  vaccinators  and  supervisors.
Interpretation: Vaccinators  and  supervisors  see  clear  beneﬁts  from  the  CTC  approach  in low  income set-
tings,  especially  in  hard-to-reach  areas  or where  cold  chain  is  weak.  Taking  advantage  of the  ﬂexibility
door  f
rld  Hoffered  by  CTC  opens  the  
at  risk are  protected.
©  2014 Wo
. Introduction
Despite immunization being one of public health’s most effec-
ive and cost-friendly interventions, over 20 million children
orldwide are under vaccinated, and remain at risk of vaccine
reventable diseases each year [1]. The need to continually keep
accines in a 2–8 ◦C cold chain is a major constraining factor for
chieving universal immunization coverage and impacts the choice
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of vaccination strategies and activities, especially in the ‘last mile’,
from health centre to vaccinee.
Many  of the vaccines used today have some inherent stability in
addition to what is currently reﬂected on their label [2–4]. Reﬂect-
ing that stability on the product label would allow for limited use
of the vaccine outside of the cold chain, without the constraints of
needing to maintain 2–8 ◦C at all times.
The cold chain in the last mile is particularly labour intensive
during immunization campaigns, such as those conducted across
sub-saharan Africa against Meningitis A. Given the size of the tar-
get populations for MenAfriVac – up to 70% of the population, all
those aged 29 years and under [5,6] – the logistical challenges in
maintaining the cold chain, from faltering electricity, poorly func-
Open access under CC BY-NC-SA license.tioning or absent equipment, to ice pack production capacity, are
signiﬁcant.
In October 2012, the Meningococcal A conjugate vaccine
MenAfriVac was  granted a label variation by the national regulatory
BY-NC-SA license.
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uthority in its country of manufacture and pre-qualiﬁed by WHO
o allow for its use in a controlled temperature chain (CTC), at tem-
eratures of up to 40 ◦C for not more than four days. This marks the
rst time a vaccine used in developing countries has been granted
uthorization to be used at ambient temperature. This paper evalu-
tes the ﬁrst use of the ﬂexibility offered by MenAfriVac’s new label
uring a mass vaccination campaign in Benin.
. Objectives
The study aimed to capture the ﬁrst ﬁeld experience using
enAfriVac in a CTC, to evaluate whether the implementation of
TC – rather than a traditional 2–8 ◦C cold chain – during a mass
ampaign is feasible, acceptable to health care workers, and to iden-
ify the beneﬁts and challenges of the approach.
. Methods
.1. Study site
The  study took place in the district of Banikoara in Northern
enin as part of the sub-National Meningitis A vaccination cam-
aign held from November 15–25, 2012. Banikoara is a rural area,
ade up of 150 villages and hamlets, divided into nine adminis-
rative zones. There is one rural hospital, one district health centre,
ine smaller health centres and three dispensaries. The population
s 210,296 (as of 2012), 70% of which are estimated to be 29 years
f age or younger (target population = 147,207). Banikoara was
elected as the site for this pilot study by the Ministry of Health in
enin, using criteria developed by WHO’s Immunization Practices
dvisory Committee as part of their guidance on the implementa-
ion of CTC campaigns for MenAfriVac [7]. During this campaign,
anikoara used a mixture of ﬁxed site and mobile/outreach teams
o vaccinate the population; all vaccination activities conducted in
anikoara were conducted using the CTC approach.
.2. The vaccine
MenAfriVac is a Meningitis A polysaccharide conjugate vaccine
esigned for use across the sub-Saharan African meningitis belt. It
omes in a 10-dose vial, with a separate diluent which contains an
luminium adjuvant, which is sensitive to freezing. As is standard
or vaccines procured through UN agencies, the vaccine comes with
 Vaccine Vial Monitor (VVM) on its label [8].
The original label for MenAfriVac stated that the vaccine should
e kept between 2 and 8 ◦C at all times. As with all vaccines, these
torage and use conditions on the vaccine’s label were approved as
art of the vaccine’s licensure by the national regulatory author-
ty in the country where the vaccine is manufactured, in this case
ndia. In October 2012, based on scientiﬁc laboratory studies and
nalyses submitted by the vaccine manufacturer (Serum Institute of
ndia), MenAfriVac’s regulatory agency of record (India) and WHO
oth approved a revision to the label which states that MenAfriVac
nd its diluent can “be stored at up to 40 ◦C for not more than four
ays immediately prior to administration, provided the vaccine has
ot reached its expiry date and the vaccine vial monitor is still valid,
nopened vials should be discarded at the end of the four days at up
o 40 ◦C. Reconstituted vaccine should be used within six hours after
econstitution, otherwise discarded.”
.3. Implementation of CTCIn order to ensure the vaccine is safe and effective at all times
hen used in a CTC, vaccination teams, comprised of one nurse
nd two volunteers relied on two indicators: the VVM, afﬁxed to2 (2014) 1431–1435
the  label of the vaccine, and a peak temperature threshold indicator
– a small laminated card with a heat sensitive sticker that changed
colour immediately upon being exposed to 40 ◦C, placed inside each
vaccine carrier. Unlike the VVM, which gradually changes colour
over time to reﬂect cumulative exposure to heat, the peak temper-
ature threshold indicator is binary, and changes colour instantly if
exposed to temperatures of 40 ◦C, without a gradual change. Teams
were instructed to check this card at the start of their day, upon
arrival at their vaccination site, and prior to opening each new vial
throughout the day. If they found that either the VVM or the peak
threshold indicator had changed colour, they were advised to stop
using the vaccines and contact their supervisor immediately.
In  addition to the standard pre-campaign training conducted in
all campaign areas in Benin, training was provided in Banikoara
on CTC prior to the campaign. This included explanations of what
CTC is, how to use the threshold indicator, a review of all forms
to complete and how to read the VVM, training on adverse events
following immunization as well as ‘scenario planning’, on how to
take advantage of the ﬂexibility provided by CTC.
Teams were asked to complete a CTC monitoring form daily as
follows: before departing the health centre, on arrival at the vac-
cination site, on administration of the last dose of vaccine and on
return to the health centre. Teams recorded the time each of these
activities took place, the number of vials they had with them at that
point, and the status of the peak threshold indicator.
At the end of each day, when teams returned to the health centre,
any vials that they had taken with them for the day but not used
were marked with a line on the label, indicating one day of CTC
exposure. All the marked vials from all teams were consolidated
and stored at ambient temperature overnight, and were the ﬁrst
vials distributed to the teams for use the next day. Teams were
instructed to use the marked vials ﬁrst. From the second day of the
campaign, teams indicated the number of marked and unmarked
vials they took with them at the start of each day on their CTC
monitoring form.
As  this was the ﬁrst use of CTC in a mass campaign, and in order
to ensure the tools were being properly used, six additional super-
visors were recruited to oversee campaign activities and provide
support to vaccinators.
3.4.  Data collection
The  data on coverage, vaccine wastage and adverse events fol-
lowing immunization were collected using standard Ministry of
Health issued forms.
Data  on CTC speciﬁc vaccine wastage was collected through the
specially designed CTC monitoring form, described above. At the
end of the campaign a survey was  conducted to evaluate the CTC
practice among the vaccinators and supervisors in Banikoara. The
survey was pre-tested with vaccinators prior to being administered.
The survey included 20 multiple choice and short answer questions.
4. Results
Three different CTC scenarios were implemented in the cam-
paign, based on the situation found in Banikoara.
The ﬁrst scenario was  the most standard option, used by all three
dispensaries and seven of the health centres. It involved keeping
the vaccines in the standard cold chain at the health centre. This
meant the vaccine was transported from the district level to the
health centre using the cold chain and placed into the fridge at dis-
trict level. On the ﬁrst morning of the campaign, vaccination teams
arrived at the health centre and retrieved their vaccines. The vac-
cines were placed into a standard vaccine carrier, without icepacks,
marking the beginning of the CTC practice.
cine 32 (2014) 1431–1435 1433
a
s
C
t
r
c
r
s
v
v
l
f
h
c
t
a
o
a
o
c
n
f
a
w
t
o
d
q
p
r
t
1
t
u
3
w
C
V
Table 1
Health worker conﬁdence in and perception of CTC.
% Vaccinators
(n = 77)
%  Supervisors
(n = 21)
Conﬁdence in CTC
Entirely  conﬁdent 69.3 52.4
Conﬁdent but need to respect the limits 29.3 47.6
Limited conﬁdence 1.3 1.0
Usefulness of CTC
Very  useful 74.0 81.0
T
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The second scenario was used in two health centres to enable
ccess to remote communities with no reliable electricity or power
ource, accessible only by difﬁcult to navigate roads. In other non-
TC campaigns, teams had to return each night to the health centre
o maintain the cold chain, limiting their ability to reach the most
emote areas. With the CTC practice, the teams collected their vac-
ines from the health centre, as described above, and set out for the
emote villages. However rather than coming back each night, they
tayed in the villages for three days, enabling them to ensure better
accination coverage of the population.
The third scenario involved starting CTC at the point when the
accines were transported from the district to the health centre
evel. This was used in the one health centre that did not have any
unctional cold chain equipment. While in previous campaigns they
ad to make a daily trek to the district capital to collect their vac-
ine, during this campaign vaccines were transported from district
o the health centre in a CTC, and then stored in a CTC for four days,
t which point a new drop off of vaccines was needed.
In  the scenario one, the vaccinators prioritized the use of vials
f vaccine which had been taken out of the cold chain and placed in
 CTC on previous days but which had not been used; on average,
ne third (33.5%) of the daily vial quantity taken out for the day
ame from unused vials from the day(s) before. A summary of the
umber of vials kept for multiple days across all scenarios can be
ound in Fig. 1. We  observed that on the ﬁrst day of the campaign,
fter the CTC training, health centre staff took out more vials than
ere necessary to reach the days’ target population in an attempt
o prevent vaccination teams running out of vaccines, which had
ccurred in previous campaigns. Following supervisory visits by
istrict staff, the health centre staff removed only the estimated
uantity of vaccine needed, plus a small buffer.
Vaccination coverage in the district was high, with 155,596 peo-
le vaccinated at the end of the campaign, equivalent to a coverage
ate of 105.7%. This proportion is comparable to the results seen in
he other zones of Benin: the overall coverage in the country was
04.7%. In Banikoara, the average time for a health care worker
o reach their vaccination site was 36 min  and 85% of the teams
sed motorbikes for transport. Each team vaccinated on average
18 persons a day (range 249–433).
Over the course of the campaign, 15,570 vials of MenAfriVac
ere used. Nine vials were discarded due to surpassing the 4 day
TC limit, ﬁve vials at day 4 and four vials on the last day. No
VMs reached their endpoint. One vial was reported as broken.
able 2
ealth worker perception of the usefulness of the CTC approach.
Vaccinators 
CTC is the most useful in
which  strategy?
Fixed  vaccination site 
Outreach vaccination site 
Both outreach and ﬁxed sites 
% Finding the
criteria  useful
or  very useful
Allows to
vaccinate more
persons
98.7  
Vaccine  carrier
is  lighter
97.4  
No  need to
freeze  the ice
pack
96.1  
Less  wastage 96.1 
No  need to
come  back
every  night
97.4  Relatively useful 26.0 19.0
Not useful 0 0
No indicators reached 40 ◦C and no vial was discarded because of
exposure to a temperature higher than 40 ◦C.
4.1. Survey
A  total of 21 supervisors and 77 vaccinators were surveyed,
92.2% of which had conducted outreach vaccination activities as
part of the campaign. Overall conﬁdence and perceived usefulness
of the CTC approach were very high among both groups (Table 1).
Most of the participants felt that the CTC practice was more
useful for outreach sessions (Table 2). Health staff identiﬁed the
top beneﬁts as allowing them to vaccinate more people per day,
reduced weight of the vaccine carrier, not needing to return to the
health centre every night and not needing to freeze ice packs.
More  than half of the interviewees (52.4% of supervisors and
54.1% of vaccinators) felt that there was no risk associated with CTC.
Those that spoke of risks often raised what can more accurately be
termed as concerns, usually about the ability to respect the CTC
limits; very few were about efﬁcacy, adverse events or wastage
(Table 3).
The  main difﬁculties in implementing CTC were identiﬁed as
reading the indicator and managing the quantity of vaccine that
should be taken out of the fridge. A small proportion of staff indi-
cated that avoiding exposing the vaccine to the sun was a challenge
(Table 4).
98.7%  of supervisors and 100% of vaccinators indicated that, if
given a choice, they would prefer to conduct their next campaign
in a CTC rather than using the traditional cold chain. Asked which
vaccines they would most like to see licensed for CTC use, most
vaccinators and supervisors cited other vaccines used in campaigns,
Supervisors
1.3% 0
39.0% 66.7%
59.7% 33.3%
Ranking  for
‘most  useful’
%  Finding the
criteria  useful
or  very useful
Ranking  for
‘most  useful’
1 100 1
2 100 2
3 100 4
4 85.7 5
5 100 3
1434 S. Zipursky et al. / Vaccine 32 (2014) 1431–1435
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.  Discussion
Over the course of the campaign, 155,000 people were vacci-
ated with MenAfriVac in a CTC. This marks the ﬁrst time since
he establishment of EPI that a campaign was conducted using a
accine with on-label guidance for use beyond the 2–8 ◦C standard
old chain range. As per the coverage rates attained, the campaign
as successful in reaching the target population. The 2013 disease
urveillance across Benin—including in the CTC area—supports this,
ith no cases of Meningitis A reported in the vaccinated population
9].
Cold chain has been a limiting factor since the inception of
he EPI. The need to keep vaccines between 2 and 8 ◦C at all
imes currently drives the way immunization strategies are devel-
ped and implemented. This study provides a ﬁrst example of the
ypes of beneﬁts that could be seen from removing that constraint,
specially for immunization campaigns and other outreach based
trategies.
While the rigorous regulatory reviews provided assurance as to
he efﬁcacy of the vaccine, the pilot provides critical validation of
able 3
ealth worker perception of the risks associated with CTC.
% Staff indicating a concern
Vaccinators (n = 77) Supervisors (n = 21)
Surpassing 40 ◦C 31.2 47.6
Surpassing 4 days 27.3 19.0
Higher  rate of AEFI 5.2 0
Vaccine  less effective 1.3 4.8
Higher  wastage 0 0hain storage status, across all scenarios of CTC use, Banikoara district.
the acceptability of the practice by health care workers. In addition
to the survey results which indicated a strong preference for CTC
when feasible, the CTC approach also has the potential to have a
positive impact on the provision of other primary health care ini-
tiatives, freeing up health care worker time and resources to keep
other regular primary care services operational (often cancelled
during campaigns) [10], rather than managing cold chain and ice
pack production logistics [11].
In addition, while the original six EPI vaccines were very sen-
sitive to heat, many new vaccines—including the MenAfriVac
diluent—are damaged by exposures to freezing temperatures while
remaining stable at higher temperatures for longer periods of
time. Studies have shown that freezing is a particular risk during
transport and outreach [12]. The CTC practice removes the risk of
freezing during these activities at the ‘last mile’.
As with any new practice, there were several challenges noted
with the CTC implementation. The biggest of these was the need
to discard unused vials after four days in a CTC, rather than hav-
ing the ability to return them to the fridge. This required close
supervision by health care workers and district health staff, and
if staff are not well trained, could lead to increases in vaccine
wastage.
Once trained, vaccinators found the peak threshold temperature
cards easy to use. However the need to ensure the vaccines are
always kept with an indicator provides an additional difﬁculty, and
vial level peak threshold indicators should be considered. Caution
must be exercised around storage of the indicator cards prior to use.
During the study two indicator cards changed colour when kept in
pockets of supervisors where temperatures surpassed 40 ◦C.
Finally,  while CTC implementation does not require the use
of cold boxes, their use during this study allowed us to protect
vaccines from high temperatures (reported ambient temperatures
reached 39 ◦C) and direct sunlight, and they remain a known ‘signal’
of vaccination activities within the community.
S. Zipursky et al. / Vaccine 32 (2014) 1431–1435 1435
Table  4
Health worker perception on the level of difﬁculty associated with CTC practice.
% of vaccinators (n = 77) % of supervisors (n = 21)
Reading the peak
temperature threshold
indicator
Easy  81.8 90.0
Midlevel difﬁculty 16.9  10.0
Difﬁcult 1.3 0
Vaccine  management Easy  80.5 75.0
Midlevel difﬁculty 19.5 20.0
Difﬁcult 0 5.0
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[13]  Smith D, Ferguson M,  Krause P, Wu T, Baca-Estrada M,  Conrad C, et al.Avoid  the sun Easy  
Midlevel difﬁculty
Difﬁcult  
Although MenAfriVac is not the only vaccine to be kept outside
he 2–8 ◦C range, it is the ﬁrst vaccine approved with this type of
ariation by WHO, and this study marks the ﬁrst demonstration
f potential beneﬁts from this type of use in low income setting.
his landmark decision opens the door for the development of
ew immunization strategies and approaches to ensure the vac-
ine reaches all those who are at risk, not just those reached by a
old chain. However in order to achieve CTC vaccine labels, close
ollaboration with manufacturers, regulatory experts and WHO
echnical staff is essential. The data that is necessary for these types
f variations is not yet systematically generated, and collaboration
o deﬁne the parameters for which additional testing should follow
n order to apply for a variation is essential [13].
As the current CTC work aims to take advantage of existing sta-
ility without requiring reformulation, the length of time available
n a CTC is likely to be constrained by the limited stability of today’s
accines. This means CTC will likely provide beneﬁts in the very last
ile, rather than alleviate cold chain capacity issues higher up in
he supply chain. However, further work to assess full impact on
ealth care workers, coverage and potential cost savings from the
pproach is needed.
In  the longer term, combining the CTC workstream with other
ore upstream efforts on vaccine development and thermostabil-
ty, and generating the data necessary to achieve a CTC license
ystematically, have the potential to enable routine EPI services
ithout cold chain for longer periods of time and should be
xplored.
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